Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart Inc. (VXRT) is a clinical-stage biotechnology company pioneering oral tablet vaccines for infectious diseases. This page aggregates official announcements, financial disclosures, and scientific developments related to its recombinant vaccine platform and clinical pipeline.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, manufacturing updates, and peer-reviewed research findings – all essential for evaluating Vaxart's position in the competitive vaccine market.
Key content focuses on tablet vaccine efficacy data, FDA communications, intellectual property developments, and comparative analyses of mucosal immunization approaches. Bookmark this page to monitor Vaxart's progress in redefining vaccine administration through its temperature-stable oral delivery system.
Vaxart (OTCQX: VXRT) will present clinical updates on its oral norovirus and COVID-19 pill vaccine programs at World Vaccine Congress Europe 2025 in Amsterdam on October 13–16, 2025. Two presentations by Dr. Sean Tucker will cover a bivalent oral norovirus vaccine with recent immunogenicity improvements and a clinical update on the oral COVID-19 vaccine covering Phase 1 to Phase 2 data.
The company highlights that its oral recombinant pill platform has generated both systemic and mucosal immune responses and shown a favorable safety and tolerability profile in clinical trials, positioning these programs as ongoing clinical-stage efforts toward potential global public-health solutions.
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company specializing in oral recombinant pill vaccines, has announced the withdrawal of its reverse stock split proposal. CEO Steven Lo emphasized that the company will maintain frequent stockholder communication while focusing on advancing their oral pill vaccine platform technology.
The decision comes after receiving constructive feedback from stockholders, with management expressing commitment to creating long-term value through their proprietary vaccine delivery platform development.
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant pill vaccines, has appointed W. Mark Watson as Lead Independent Director. Watson, a Certified Public Accountant with over 50 years of experience, including 40+ years at Deloitte, has served on Vaxart's Board since August 2022.
The company is implementing two significant governance changes: appointing Watson as Lead Independent Director and adopting a Director stock ownership policy to align Board interests with stockholders. Additionally, Vaxart is actively seeking stockholder approval for a reverse stock split, with voting deadline set for September 18, 2025, at 11:59 p.m. ET. The special stockholder meeting will be held virtually on September 19, 2025, at 8:30 a.m. PT.
Vaxart (OTCQX: VXRT) has reported promising Phase 1 data for its second-generation norovirus oral pill vaccine. The vaccine demonstrated a 25-fold increase in GII.4 fecal IgA response and a 10-fold increase in GI.I fecal IgA response over baseline with high-dose administration.
The second-generation constructs showed superior immunologic responses compared to first-generation versions, which previously demonstrated a 30% relative reduction in infection versus placebo in Phase 2b trials. The company's vaccine technology uniquely induces intestinal immunity, potentially offering stronger protection at the virus entry site.
With norovirus causing 685 million infections globally annually and representing a $10+ billion economic impact in the U.S., Vaxart is seeking partnerships to advance to Phase 2 trials by late 2025, with potential Phase 3 trials beginning in 2026.
Vaxart (NASDAQ:VXRT) announced the adjournment of its 2025 special meeting of stockholders to September 19, 2025. The meeting, which includes a critical reverse stock split proposal to maintain Nasdaq listing, was postponed to give shareholders more time to consider recent board changes, potential governance modifications, and upcoming company disclosures.
CEO Steven Lo emphasized the importance of maintaining Nasdaq listing for advancing the company's science and maximizing shareholder value. The virtual meeting will be accessible to stockholders of record as of July 29, 2025, who can vote until 11:59 p.m. ET on September 18, 2025.
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company specializing in oral recombinant pill vaccines, has announced its participation in the upcoming H.C. Wainwright Global Investment Conference.
Management will deliver their presentation on Monday, September 8, 2025, at 12:00 PM ET. The presentation will be accessible via webcast on the company's investor relations website, with a replay available for 30 days after the event. Investors can arrange meetings with management through their H.C. Wainwright representatives.
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant pill vaccines, announced the retirement of its Chairman Michael J. Finney, Ph.D. from the Board of Directors and Science and Technology Committee, effective September 30, 2025.
The Board of Directors will convene to discuss leadership succession, composition, and governance matters while considering stockholder feedback. The company aims to maintain its focus on advancing its scientific initiatives and oral pill vaccine platform development.
Vaxart (NASDAQ:VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, has received an extension from the Nasdaq Hearings Panel to regain compliance with the minimum bid price requirement. The company must meet three critical conditions: obtain stockholder approval for a reverse stock split by September 5, 2025, complete the reverse split by October 6, 2025, and demonstrate compliance with the Bid Price Rule by October 17, 2025.
During an August 14 hearing, Vaxart's management presented their compliance plan, highlighting modifications to their reverse stock split proposal, including a narrower split ratio range and reduced authorized shares. CEO Steven Lo emphasized the importance of maintaining Nasdaq listing for the company's future success.
Vaxart (OTCQX: VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, will host a virtual stockholder fireside chat on August 20, 2025, at 4:30 p.m. ET to discuss its reverse stock split proposal. Leading proxy advisory firms ISS and Glass Lewis have recommended stockholders support the proposal, which aims to regain Nasdaq compliance.
The company's management team will address stockholder questions during the event, with investors able to submit questions in advance. Stockholders of record as of July 29, 2025, can vote on the proposal until September 4, 2025.
[]Vaxart (OTCQX: VXRT) reported Q2 2025 financial results and provided significant updates across its vaccine pipeline. The company reported revenue of $39.7M (vs $6.4M in Q2 2024) and a net loss of $15.0M. Key developments include positive topline data from their second-generation norovirus vaccine trial, showing statistically significant increases in blocking antibodies (141% for GI.1 and 94% for GII.4) compared to first-generation constructs.
The company's COVID-19 Phase 2b trial enrolled approximately 5,000 participants before receiving a stop work order, with follow-up continuing for all dosed participants. Vaxart ended Q2 with $26.3M in cash and equivalents, projecting runway into 2026. The company will hold a special stockholder meeting on September 5, 2025, to vote on a potential reverse stock split to regain Nasdaq compliance.
FAQ
What is the current stock price of Vaxart (VXRT)?
What is the market cap of Vaxart (VXRT)?
